Novartis (NVS)
(Real Time Quote from BATS)
$97.34 USD
-0.16 (-0.16%)
Updated May 2, 2024 02:02 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVS 97.34 -0.16(-0.16%)
Will NVS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVS
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Other News for NVS
H.C. Wainwright sees Actinium as buyout candidate after Mariana deal
Genmab reports Q1 revenue increased 46% vs. last year
Novartis to buy Mariana Oncology for $1B upfront
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Novartis Is Tracking Well Above the Industry